Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children

Phytomedicine

Volumn 14, Issue 2-3, 2007, Pages 96-101

  Kubo, Tomohiro ^a   Nishimura, Hidekazu ^b  

^a Self Defense Force Sendai Hospital   (Japan)

^b SENDAI CITY MEDICAL CENTER   (Japan)

Author keywords

Influenza; Japanese herbal medicine; Mao to; Oseltamivir; Pediatrics

Indexed keywords

HERBACEOUS AGENT; MAO TO; UNCLASSIFIED DRUG;

ADOLESCENT; AGE DISTRIBUTION; ANTIPYRETIC ACTIVITY; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; INFANT; INFLUENZA; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADMINISTRATION, ORAL; ADOLESCENT; ANALGESICS, NON-NARCOTIC; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; DNA, VIRAL; DRUGS, CHINESE HERBAL; FEMALE; FEVER; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA, HUMAN; JAPAN; MALE; MEDICINE, CHINESE TRADITIONAL; OSELTAMIVIR; PHYTOTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 33846368162     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2006.09.015     Document Type: Article

References (12)

1. Cooper N.J., Sutton A.J., Abrams K.R., Wailoo A., Turner D.A., and Nicholson K.G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. Br. Med. J. 326 (2003) 1235-1241
2. Ellis J.S., Chakraverty P., and Clewley J.P. Genetic and antigenic variation in the haemagglutinin of recently circulating human influenza A (H3N2) viruses in the United Kingdom. Arch. Virol. 140 (1995) 1889-1904
3. Gubareva L.V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103 (2004) 199-203
4. Kainuma M., Sakai S., Sekiya N., Mantani N., Ogata N., Shimada Y., and Terasawa K. The effects of a herbal medicine (Mao-to) in patients with chronic hepatitis C after injection of IFN-β. Phytomedicine 11 (2004) 5-10
5. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
6. Kurokawa M., Kumada C.A., Yamamura J., Kamiyama T., and Shiraki K. Antipyretic activity of cinnamyl derivatives and related compounds in influenza virus-infected mice. Eur. J. Pharmacol. 348 (1998) 45-51
7. Kurokawa M., Tsurita M., Brown J., Fukuda Y., and Shiraki K. Effect of interleukin-12 level augmented by Kakkon-to, a herbal medicine, on the early stage of influenza infection in mice. Antivir. Res. 56 (2002) 183-188
8. Kuroki H., and Kimoto H. Experience of combined western and oriental medicine for the treatment of influenza and measles in children. Jpn. Pediatr. Soc. Orient. Med. 20 (2004) 28-30 (in Japanese)
9. Mantani N., Andoh T., Kawamata H., Terasawa K., and Ochiai H. Inhibitory effect of Ephedrae herba, an oriental traditional medicine, on the growth of influenza A/PR/8 virus in MDCK cells. Antivir. Res. 44 (1999) 193-200
10. Nagai T., and Yamada H. In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine "Sho-seiryu-to" and its mode of action. Int. J. Immunopharmacol. 16 (1994) 605-613
11. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., and Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1recepter antagonist and soluble tumor necrosis factor receptor. Blood 83 (1994) 113-118
12. Wooltorton E. Oseltamivir (Tamiflu) unsafe in infants under 1 year old. Can. Med. Assoc. J. 170 (2004) 336